These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 38285598

  • 1. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
    Paik JM, Tesfaye H, Curhan GC, Zakoul H, Wexler DJ, Patorno E.
    JAMA Intern Med; 2024 Mar 01; 184(3):265-274. PubMed ID: 38285598
    [Abstract] [Full Text] [Related]

  • 2. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Chen WM, Yeh YH, Kuo CT, See LC, Lip GYH.
    Cardiovasc Diabetol; 2022 Jun 28; 21(1):118. PubMed ID: 35765074
    [Abstract] [Full Text] [Related]

  • 3. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Tang H, Lu Y, Donahoo WT, Shao H, Shi L, Fonseca VA, Guo Y, Bian J, Guo J.
    Ann Intern Med; 2024 Aug 28; 177(8):1004-1015. PubMed ID: 39008852
    [Abstract] [Full Text] [Related]

  • 4. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM, Tan KCB, Lam DCL, Cheung BMY, Wong ICK, Kwok WC, Sing CW, Cheung CL.
    JAMA Netw Open; 2023 Jan 03; 6(1):e2251177. PubMed ID: 36648944
    [Abstract] [Full Text] [Related]

  • 5. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S, Zhou J, Leung KSK, Wai AKC, Jeevaratnam K, King E, Liu T, Wong WT, Chang C, Wong ICK, Cheung BMY, Tse G, Zhang Q.
    Cardiovasc Drugs Ther; 2023 Jun 03; 37(3):561-569. PubMed ID: 35142921
    [Abstract] [Full Text] [Related]

  • 6. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
    Xu Y, Boyle TA, Lyu B, Ballew SH, Selvin E, Chang AR, Inker LA, Grams ME, Shin JI.
    J Gen Intern Med; 2024 May 03; 39(7):1112-1121. PubMed ID: 38191976
    [Abstract] [Full Text] [Related]

  • 7. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study.
    Jeong HE, Park S, Noh Y, Bea S, Filion KB, Yu OHY, Jang SH, Cho YM, Yon DK, Shin JY.
    BMC Med; 2023 Feb 10; 21(1):47. PubMed ID: 36765407
    [Abstract] [Full Text] [Related]

  • 8. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
    Zhuo M, D'Andrea E, Paik JM, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Patorno E.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2235995. PubMed ID: 36219443
    [Abstract] [Full Text] [Related]

  • 9. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, Tam WWS, Morze J, Rynkiewicz A, Xin Y, Wu O, Providencia R, Kwong JS.
    Cochrane Database Syst Rev; 2021 Oct 25; 10(10):CD013650. PubMed ID: 34693515
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J, Bates BA, Setoguchi S, Gerhard T, Dave CV.
    Cardiovasc Diabetol; 2023 Mar 10; 22(1):54. PubMed ID: 36899387
    [Abstract] [Full Text] [Related]

  • 11. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG, Van Houten HK, Deng Y, Mandic PK, Ross JS, Montori VM, Shah ND.
    JAMA Netw Open; 2021 Feb 01; 4(2):e2035792. PubMed ID: 33523188
    [Abstract] [Full Text] [Related]

  • 12. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL, Halvorson AE, Hackstadt AJ, Hung AM, Greevy R, Grijalva CG, Elasy TA, Roumie CL.
    Ann Intern Med; 2023 Jun 01; 176(6):751-760. PubMed ID: 37155984
    [Abstract] [Full Text] [Related]

  • 13. Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis.
    Kristensen KB, Henriksen DP, Hallas J, Pottegård A, Lund LC.
    Diabetologia; 2021 Jul 01; 64(7):1563-1571. PubMed ID: 33715024
    [Abstract] [Full Text] [Related]

  • 14. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.
    Barkmeier AJ, Herrin J, Swarna KS, Deng Y, Polley EC, Umpierrez GE, Galindo RJ, Ross JS, Mickelson MM, McCoy RG.
    Ophthalmol Retina; 2024 Oct 01; 8(10):943-952. PubMed ID: 38735641
    [Abstract] [Full Text] [Related]

  • 15. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
    Newman TV, Munshi KD, Neilson LM, Good CB, Swart ECS, Huang Y, Henderson R, Parekh N.
    J Manag Care Spec Pharm; 2021 Apr 01; 27(4):435-443. PubMed ID: 33769857
    [Abstract] [Full Text] [Related]

  • 16. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
    Lyu B, Grams ME, Chang A, Inker LA, Coresh J, Shin JI.
    Am J Cardiol; 2022 Feb 15; 165():124-130. PubMed ID: 34937658
    [Abstract] [Full Text] [Related]

  • 17. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
    D'Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E.
    JAMA Intern Med; 2023 Mar 01; 183(3):242-254. PubMed ID: 36745425
    [Abstract] [Full Text] [Related]

  • 18. SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation.
    Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Yeh YH, Kuo CT, See LC, Lip GYH.
    J Clin Endocrinol Metab; 2024 Sep 16; 109(10):2617-2629. PubMed ID: 38466894
    [Abstract] [Full Text] [Related]

  • 19. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
    Lui DTW, Tang EHM, Wu T, Au ICH, Lee CH, Woo YC, Tan KCB, Wong CKH.
    Cardiovasc Diabetol; 2023 Feb 24; 22(1):40. PubMed ID: 36829226
    [Abstract] [Full Text] [Related]

  • 20. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
    Patorno E, Pawar A, Bessette LG, Kim DH, Dave C, Glynn RJ, Munshi MN, Schneeweiss S, Wexler DJ, Kim SC.
    Diabetes Care; 2021 Mar 24; 44(3):826-835. PubMed ID: 33495295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.